Skip to main content
FinSpry Logo
FinSpry
RNAC logo
RNAC
(NASDAQ)
Cartesian Therapeutics, Inc.
$9.27-- (--)
Loading... - Market loading
OverviewFinancialsForecastStatisticsDividendsHistoricalProfile

Cartesian Therapeutics (RNAC) Stock Price & Financial Analysis

Cartesian Therapeutics Stock Price Chart

Price Chart

Loading chart...

Financial Metrics & Key Statistics

Fundamental metrics, valuation ratios, and profitability indicators

Day's Range$8.89 - $9.31
52-Week High$11.00
52-Week Low$5.60
Open$9.12
Volume68.35K
Average Volume (3M)120.44K
Market Cap248.95M
Shares Outstanding26.86M
Price to Sales (P/S)140.25
Price to Book (P/B)-1.68
EV/EBITDA-0.97
Revenue (TTM)1.77M
Net Income (TTM)-151.77M
Free Cash Flow (TTM)-77.37M
EPS (TTM)$-5.77
Profit Margin-8550.65%
Operating Margin-5144.51%
50-Day MA$9.04
200-Day MA$7.68
52-Week Change-12.88%
Annual Dividend$0.00
Dividend Yield0.00%

Frequently Asked Questions About Cartesian Therapeutics

What is the current stock price for RNAC?

As of the latest trading session, RNAC stock trades at $9.27. The 52-week range is $5.60–$11.00, with a day range of $8.89–$9.31.

What is the P/E ratio for RNAC?

The P/E ratio (Price-to-Earnings) for RNAC is shown in the Key Statistics section. This valuation metric helps compare Cartesian Therapeutics, Inc. to industry peers.

Does RNAC pay dividends?

Cartesian Therapeutics does not currently pay a regular dividend. The company reinvests earnings into growth and operations. Check the Dividends tab for historical dividend information.

What do analysts recommend for RNAC?

Based on 3 analysts, the consensus for RNAC is Buy.

What is the market cap of RNAC?

Cartesian Therapeutics's market capitalization is $248.9M, classifying it as a micro-cap company. Cartesian Therapeutics operates in the Healthcare sector within the Biotechnology industry.